Dihydroetorphine: Physical dependence and stereotypy after continuous infusion in the rat

European Journal of Pharmacology

Volumn 387, Issue 1, 2000, Pages 31-37

  Aceto, Mario D ^a   Scates, Susan M ^a   Harris, Louis S ^a   Ji, Zhen ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Continuous infusion; Dihydroetorphine; Morphine; Physical dependence; Rat; Stereotypy

Indexed keywords

DIHYDROETORPHINE; MORPHINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; DRUG WITHDRAWAL; IRRITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; WEIGHT REDUCTION; WET DOG SHAKES;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; ETORPHINE; INFUSIONS, PARENTERAL; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 0033985879     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00758-X     Document Type: Article

References (41)

1. Aceto M.D. Assessment of physical dependence techniques for the evaluation of abused drugs. Adler M.W., Cowan A. Modern Methods in Pharmacology: Testing and Evaluation of Drugs of Abuse. 1990;76-79 Wiley-Liss, New York, NY.
2. Aceto M.D., Harris L.S., Bowman E.R. Etorphines: μ-opioid receptor-selective antinociception and low physical dependence capacity. Eur. J. Pharmacol. 338:1997;215-223.
3. Aceto M.D., Scates S.M., Razdan R.K., Martin B.R. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J. Pharmacol. Exp. Ther. 287:1998;598-605.
4. Aghajanian G.K. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature. 267:1978;186-188.
5. Akera T., Brody T.M. The addiction cycle to narcotics in the rat and its relation to catecholamines. Biochem. Pharmacol. 17:1968;675-688.
6. Altman J., Everitt B.J., Glautier S., Markou A., Nutt D., Oretti R., Phillips G.D., Robbins W.W. The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology. 125:1996;285-345.
7. Beardsley P.M., Harris L.S. Evaluation of the discriminative and reinforcing effects of dihydroetorphine. Drug Alcohol Depend. 48:1997;77-84.
8. Bentley K.W., Hardy D.G. Novel analgesics and molecular rearrangements in the morphine-thebaine group: III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J. Am. Chem. Soc. 89:1967;3281-3292.
9. 1 ganglioside. Brain Res. 575:1992;13-24.
10. 1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition. J. Pharmacol. Exp. Ther. 260:1992;182-186.
11. Crain S.M., Shen K.-F. Etorphine elicits unique inhibitory-agonist and excitatory antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Rapaka R.S., Sorer H. Discovery of Novel Opioid Medications. NIDA Research. Monograph Series. 147:1995;234-267 Government Printing Office, Washington, DC.
12. Crain S.M., Shen K.-F. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc. Natl. Acad. Sci. 92:1995;10540-10544.
13. 1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells. Brain Res. 741:1996;275-283.
14. Di Chiara G., North R.A. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13:1992;185-193.
15. Huang M., Wang D.X., Qin B.Y. Dihydroetorphine, a potent opioid with low dependent potential. Regul. Pept. 50:1994;S81-S82.
16. Johansson E.K., Tucker S.M., Ginn H.B., Martin B.R., Aceto M.D. Functional and dispositional tolerance develops during continuous cocaine exposure. Eur. J. Pharmacol. 17:1991;155-162.
17. Kamei J., Susuki T., Misawa M., Nagase H., Kasuya Y. Antinociceptive effect of dihydroetorphine in diabetic mice. Eur. J. Pharmacol. 275:1995;109-113.
18. Keith D.E., Murray S.R., Zaki P.A., Chu P.C., Lissin D.V., Kang L., Evans C.J., Von Zastrow M. Morphine activates opioid receptors without causing their rapid internalization. J. Biol. Chem. 271:1996;19021-19024.
19. Keith D.E., Anton B., Murray S.R., Zaki P.A., Lissin D.V., Monteillet-Agius G., Stewart P.L., Evans C.J., Von Zastrow M. μ-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol. Pharmacol. 53:1998;377-384.
20. Magnan J., Paterson S.J., Tavani A., Kosterlitz H.W. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch. Pharmacol. 319:1982;197-205.
21. Magos L. Persistence of the effects of amphetamine on stereotyped activity in rats. Eur. J. Pharmacol. 6:1969;200-201.
22. Maldonado R., Stinis L., Gold L.H., Koob G.F. Role of different brain structures in the expression of physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261:1992;669-677.
23. Martin T.J., Kim S.A., Harris L.S., Smith J.E. Potent reinforcing effects of dihydroetorphine in rats. Eur. J. Pharmacol. 324:1997;141-145.
24. Nestler E.J., Tallman J.F. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol. Pharmacol. 33:1988;127-132.
25. Nestler E.J., Hope B.T., Widnell K.I. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 11:1993;995-1006.
26. Niwa M., al-Essa L.Y., Ohta S., Kohno K., Nozaki M., Tsurumi K., Iwamura T., Katoaka T. Opioid receptor interactions and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine. Life Sci. 56:1995;PL395-PL400.
27. Patrick G.A., Harris L.S. Dihydroetorphine exhibits atypical physical dependence in the chronically infused rat. Problems of Drug Dependence: Proceedings of the 58th Annual Scientific Meeting, the College on Problems of Drug Dependence. Harris L.S. NIDA Research Monograph Series. 174:1997;85 U.S. Government Printing Office, Washington, DC.
28. Qin B.Y. Research advances of dihydroetorphine: from analgesia to detoxification. New Drugs Clin. Rem. 2:1993;119-123. (English abstract).
29. Schuster C.R., Johanson C.E. Animal models of self-administration. Adv. Substance Abuse. 2:1981;219-297.
30. Schwartz T.W., Ijzerman A.P. Principles of agonism: undressing efficacy. Trends Pharmacol. Sci. 19:1998;433-436.
31. Shen K.-F., Crain S.M. Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid 'dependence' without tolerance. Brain Res. 597:1992;74-83.
32. Shen K.-F., Crain S.M. Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res. 636:1994;286-297.
33. Shen K.-F., Crain S.M. Specific N- or C-terminus modified dynorphin and β-endorphin peptides can selectively block excitatory receptor functions in sensory neurons and unmask potent inhibitory effects of opioid agonists. Brain Res. 673:1995;30-38.
34. Smart D., Lambert D.G. The stimulatory effects of opioids and their possible role in the development of tolerance. Trends Pharmacol. Sci. 17:1996;264-268.
35. Teiger D.G. Induction of physical dependence on morphine codeine and meperidine in the rat by continuous infusion. J. Pharmacol. Exp. Ther. 190:1974;408-415.
36. Tokuyama S., Takahashi M., Kaneto H. Antinociceptive effect of dihydroetorphine and its tolerance/dependence liability in mice. Biol. Pharm. Bull. 16:1993;774-777.
37. Wang D.X., Liu Y.S., Qin B.Y. Experimental treatment of dihydroetorphine and naloxone on morphine-dependent rats and monkeys. Chin. J. Pharmacol. Toxicol. 6:1992;36-40. (English abstract).
38. Wang S.F., Yan D.K., Yang Z., Qin B.Y., Wei Y.J., Li F.Y. Clinical investigation on detoxification of heroin addiction with dihydroetorphine hydrochloride. Chin. J. Clin. Pharmacol. 8:1992;106-112. (English abstract).
39. Wang D.X., Lu X.Q., Qin B.Y. Dihydroetorphine is a μ-receptor-selective ligand. J. Pharm. Pharmacol. 47:1995;669-673.
40. Whistler J.L., Von Zastrow M. Morphine-activated morphine receptors elude desensitization by β-arrestin. Cell Biol. 95:1998;9914-9919.
41. Xu J.Y., Fujimoto J.M., Tseng L.F. Involvement of the supraspinal ε- and μ-opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse. J. Pharmacol. Exp. Ther. 263:1992;246-252.